Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NR1I3 | Q14994 | 11/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234466 | 0.90 | MEN1 (0.47) | ACEKMT2AMEN1NR1I3GAA | |
| SCHEMBL2238532 | 0.90 | MEN1 (0.47) | ACEKMT2AMEN1NR1I3GAA | |
| SCHEMBL2236787 | 0.90 | MEN1 (0.47) | ACEKMT2AMEN1NR1I3GAA | |
| SCHEMBL2236260 | 0.88 | ACE (0.34) | LMNATSHRUSP2ACEKMT2A | |
| SCHEMBL2382108 | 0.87 | ACE (0.41) | ACEKMT2AMEN1NR1I3GAA | |
| SCHEMBL2234065 | 0.87 | NR1I3 (0.34) | LMNATSHRUSP2ACEKMT2A | |
| SCHEMBL2236269 | 0.87 | ACE (0.33) | LMNATSHRUSP2ACEKMT2A | |
| SCHEMBL2237273 | 0.87 | ACE (0.36) | LMNAACE | |
| SCHEMBL2235348 | 0.86 | ACE (0.34) | LMNATSHRUSP2ACEKMT2A | |
| SCHEMBL2235003 | 0.86 | SLC6A2 (0.41) | KMT2AMEN1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | LMNA 2382/4885TSHR 48/4885USP2 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.